Want a deeper scan?
Get a guided tour of your organization’s security posture from an UpGuard team member.


This is a preliminary report on Endocyte’s security posture. If you want in-depth, always up-to-date reports on Endocyte and millions of other companies, start a free trial today. UpGuard is the new standard in third-party risk management and attack surface management. Our security ratings engine monitors billions of data points each day.
Start monitoring Endocyte

UpGuard Security Rating

/ 950
This is a 0-950 security rating for Endocyte. The higher the rating, the more likely Endocyte has good security practices. For complete visibility of the security posture of Endocyte, start a free trial of UpGuard.

Company info

P. Ron Ellis
Last updated
Last updated
Last updated today

Security report for Endocyte

Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO).
Last updated today

Endocyte Data Breaches and Security News

Relevant news, breaches and security articles relating to Endocyte.

More security reports

Compare Endocyte's security performance with other companies.

Leader in Third Party & Supplier Risk Management Software

See how UpGuard shapes up against other platforms in the market.
Free instant security score

How secure is your organization?

Request a free cybersecurity report to discover key risks on your website, email, network, and brand.
  • Check icon
    Instant insights you can act on immediately
  • Check icon
    Hundreds of risk factors including email security, SSL, DNS health, open ports and common vulnerabilities
Website Security scan resultsWebsite Security scan rating
Want a full vendor security report for this company?
Start your free trial and unlock real-time insights to identify and assess vendor risks.